

Alessia Levaggi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7663685/publications.pdf>

Version: 2024-02-01

28
papers

1,216
citations

623734

14
h-index

501196

28
g-index

29
all docs

29
docs citations

29
times ranked

1617
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617.	6.4	12
2	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093181.	1.3	7
3	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
4	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). <i>European Journal of Cancer</i> , 2018, 99, 9-19.	2.8	10
5	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. <i>Breast</i> , 2017, 33, 104-108.	2.2	16
6	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39
7	The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 346.	2.6	30
8	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017, 8, 44800-44810.	1.8	4
9	Treatment with aromatase inhibitors and markers of cardiovascular disease. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 261-267.	2.5	7
10	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1153-1161.	3.1	8
11	Chemotherapy-induced premature ovarian failure and its prevention in premenopausal breast cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 5-7.	0.6	14
12	Follow-up strategies for women treated for early breast cancer. <i>The Cochrane Library</i> , 2016, 2016, CD001768.	2.8	138
13	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 117-126.	2.5	12
14	Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fcγ3RIIIA/Fcγ3RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. <i>Journal of Translational Medicine</i> , 2015, 13, 324.	4.4	40
15	Protecting Ovaries During Chemotherapy Through Gonad Suppression. <i>Obstetrics and Gynecology</i> , 2015, 126, 901.	2.4	19
16	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2632.	7.4	180
17	Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4557-4561.	3.7	14
18	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 675-683.	7.7	169

#	ARTICLE	IF	CITATIONS
19	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013, 22, 470-475.	2.2	13
20	Fertility counseling of young breast cancer patients. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S68-80.	1.4	16
21	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1391-1405.	2.4	19
22	Stevens-Johnson syndrome after treatment with bendamustine. <i>Leukemia Research</i> , 2012, 36, e153-e154.	0.8	11
23	Medical approaches to preservation of fertility in female cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 387-396.	1.8	35
24	Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives. <i>Cancer Treatment Reviews</i> , 2011, 37, 208-211.	7.7	15
25	Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 269-76.	7.4	311
26	Letrozole withdrawal response in locally advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 1927-1928.	1.2	3
27	Use in current clinical practice of 70-gene signature in early breast cancer. <i>International Journal of Cancer</i> , 2010, 127, 2736-2737.	5.1	2
28	Estrone Sulphate, FSH, and Testosterone Levels in Two Male Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Oncologist</i> , 2010, 15, 1270-1272.	3.7	13